From Lab to Clinic: The Journey of Peptide Therapeutics
The journey of Peptide Therapeutic from lab to clinic involves a complex process of discovery, optimization, preclinical development, and clinical trials. Peptide Therapeutic are biologically active molecules composed of amino acids and can be designed to selectively target specific cellular receptors or enzymes, offering a highly specific mode of action. However, their journey from the laboratory to clinical use is often challenging due to their inherent instability, immunogenicity, and potential toxicity.
To overcome these challenges, Peptide Therapeutics undergo a rigorous process of optimization, including modifications to enhance their stability, pharmacokinetic properties, and selectivity. In vitro and in vivo preclinical studies are then conducted to evaluate their efficacy and safety before advancing to clinical trials. Clinical trials involve a series of phases, starting with phase I trials to evaluate safety and pharmacokinetics, followed by phase II and III trials to assess efficacy and safety in a larger patient population. If successful, the peptide therapeutic is submitted for regulatory approval, and if granted, it can be prescribed to patients in clinical practice.
Read More:
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian